Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06556407 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Renal Denervation on Bood Pressure in Patients on Hemodialysis

Study acronym: RDN-HD
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Nov 1, 2025 to Dec 1, 2026
    • Start date: Mar 2, 2024 to Mar 4, 2024
    • Eligibility criteria expanded, about 7 words
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The RDN-HD Study is a prospective, single-center feasibility study. All patients included will undergo endovascular ultrasound-based RDN (no sham group, no blinding). The purpose of the RDN-HD Study is to demonstrate that ultrasound-based RDN is safe in patients with TRH and ESRD hemodialysis and reduces 24-h ambulatory BP.
Trial Details
NCT Number NCT06556407
Lead Sponsor University of Erlangen-Nürnberg Medical School
Conditions
(from sponsor)		 Treatment Resistant Hypertension, Chronic Hemodialysis
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov